Literature DB >> 17418568

1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors.

Thomas Lübbers1, Markus Böhringer, Luca Gobbi, Michael Hennig, Daniel Hunziker, Bernd Kuhn, Bernd Löffler, Patrizio Mattei, Robert Narquizian, Jens-Uwe Peters, Yves Ruff, Hans Peter Wessel, Pierre Wyss.   

Abstract

In a search for novel DPP-IV inhibitors, 2-aminobenzo[a]quinolizines were identified as submicromolar HTS hits. Due to the difficult synthetic access to this compound class, 1,3-disubstituted 4-aminopiperidines were used as model compounds for optimization. The developed synthetic methodology and the SAR could be transferred to the 2-aminobenzo[a]quinolizine series, leading to highly active DPP-IV inhibitors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17418568     DOI: 10.1016/j.bmcl.2007.03.072

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  6 in total

1.  Libraries of 2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-amine derivatives via a multicomponent assembly process/1,3-dipolar cycloaddition strategy.

Authors:  Brett A Granger; Kyosuke Kaneda; Stephen F Martin
Journal:  ACS Comb Sci       Date:  2011-11-10       Impact factor: 3.784

2.  Systemic bile acid sensing by G protein-coupled bile acid receptor 1 (GPBAR1) promotes PYY and GLP-1 release.

Authors:  C Ullmer; R Alvarez Sanchez; U Sprecher; S Raab; P Mattei; H Dehmlow; S Sewing; A Iglesias; J Beauchamp; K Conde-Knape
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

3.  Novel hypoglycemic dihydropyridones serendipitously discovered from O- versus C-alkylation in the synthesis of VMAT2 antagonists.

Authors:  Yuli Xie; Anthony Raffo; Masanori Ichise; Shixian Deng; Paul E Harris; Donald W Landry
Journal:  Bioorg Med Chem Lett       Date:  2008-08-07       Impact factor: 2.823

4.  Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitor.

Authors:  Hiroyuki Nojima; Kazuhiko Kanou; Genki Terashi; Mayuko Takeda-Shitaka; Gaku Inoue; Koichiro Atsuda; Chihiro Itoh; Chie Iguchi; Hajime Matsubara
Journal:  BMC Struct Biol       Date:  2016-08-05

5.  Nonadditivity in public and inhouse data: implications for drug design.

Authors:  D Gogishvili; E Nittinger; C Margreitter; C Tyrchan
Journal:  J Cheminform       Date:  2021-07-02       Impact factor: 5.514

6.  Strong nonadditivity as a key structure-activity relationship feature: distinguishing structural changes from assay artifacts.

Authors:  Christian Kramer; Julian E Fuchs; Klaus R Liedl
Journal:  J Chem Inf Model       Date:  2015-03-11       Impact factor: 4.956

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.